Trial Profile
A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Aug 2022
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary) ; Carboplatin; Docetaxel; Paclitaxel; Rifampicin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 06 Aug 2022 Results assessing the effect of the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics (PK) of pevonedistat in patients with advanced solid tumors published in the Investigational New Drugs
- 08 Mar 2021 Status changed from active, no longer recruiting to completed.
- 05 Jan 2021 Planned End Date changed from 31 Dec 2020 to 28 Feb 2021.